Cargando…
Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity
To date, parathyroid hormone is the only clinically available bone anabolic drug. The major difficulty in the development of such drugs is the lack of clarification of the mechanisms regulating osteoblast differentiation and bone formation. Here, we report a peptide (W9) known to abrogate osteoclast...
Autores principales: | Furuya, Yuriko, Inagaki, Atsushi, Khan, Masud, Mori, Kaoru, Penninger, Josef M., Nakamura, Midori, Udagawa, Nobuyuki, Aoki, Kazuhiro, Ohya, Keiichi, Uchida, Kohji, Yasuda, Hisataka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581422/ https://www.ncbi.nlm.nih.gov/pubmed/23319583 http://dx.doi.org/10.1074/jbc.M112.426080 |
Ejemplares similares
-
Stimulation of bone formation in cortical bone of the mice treated with a novel bone anabolic peptide with osteoclastogenesis inhibitory activity
por: Furuya, Yuriko, et al.
Publicado: (2012) -
Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis
por: Ozaki, Yuki, et al.
Publicado: (2017) -
From discovery of RANKL to clinical application of anti-human RANKL antibody
por: Yasuda, Hisataka, et al.
Publicado: (2012) -
Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor-κB Ligand-neutralizing Antibody: EVIDENCE FOR BONE ANABOLIC EFFECT OF PARATHYROID HORMONE IN MICE WITH FEW OSTEOCLASTS
por: Furuya, Yuriko, et al.
Publicado: (2011) -
The molecular mechanism of osteoclastogenesis: ODF/RANKL-dependent and independent pathways
por: Suda, T, et al.
Publicado: (2001)